Thousands of insider filings. The signals that actually mattered.

CFO Taleghani put in ~$100K on Aug 11, raising his stake 27% — real C-suite money into deep weakness, RSI a washed-out 22.3 and price 30% off the 52w low after a 24% drawdown. But it's a single director-plus-CFO with no cluster, and news is negative: Q1 FY27 revenue reset, Barclays downgrade to Underweight $5, Citi Sell at $4.75, so this is a small capitulation nibble only.

CEO Cox put in ~$1.18M on Aug 10 as a brand-new open-market stake (ΔOwn 999), 2 unique insiders clustered, into a stock riding fresh momentum — Q2 beat drove a data-center-demand surge, BNP upgrade to Outperform and multiple PT hikes toward $62. RSI 57, above MA20, sector beating SPY +2.1%, clean net flow; entry only 3% above insider price. Capped at A not A+ because it's 41% off the 52w low (extended, not a bottom setup); swing target +10% to ~$28.48 within 30 days.

CEO/President Charles Fitzgerald put in $1.28M on Aug 10, raising his stake 28% — second insider buying alongside, so a real 2-person C-suite cluster. Clean net flow, buy price ($35.94) essentially at current ($36.42), profitable medical REIT with solid FFO of $1.04/share and stable 95%-leased outpatient portfolio; sits 25% off its 52w low, RSI 43, but just below MA20/50 keeps it from A+. Real estate sector is lagging SPY by ~4% and 633M debt vs 10M cash is the main watch-out.

Four-insider cluster including the CFO/GC on Aug 10, top delta 19%, buying near the $22.69 52w low (17.7% off low) with RSI 46 — insurer sits deeply off its $54.90 high. Financials sector is beating SPY by ~10%, a real tailwind, and UBS just reiterated Buy. Size is modest ($288K total across four names) and the fundamentals are shaky — Q1 net loss, negative revenue growth, and a $464.8M impairment quarter — so this is a small position only.

President/CEO Larry Wood bought ~$498K solo, delta_own 8%, single insider (no cluster) — real C-suite money into a name near its 52w low after a ~49% drawdown. Fundamentals support the thesis with 19% revenue growth and 64% gross margin, and the healthcare sector is beating SPY by ~13%. But RSI 70 is already extended into resistance at ma50, and a securities class-action lawsuit over an alleged handpiece discount program that inflated recurring revenue is a serious overhang — small position only.

CFO Lemasters bought $827K on Aug 7, raising his stake 22% — real C-suite conviction with meaningful ownership increase at exactly his purchase price. Cold-storage REIT is 32% off its 52w low, RSI 42, below both MAs but stabilizing; clean net flow. Q1 EBITDA up 3.3% with maintained guidance supports the thesis, though EPS missed and REIT sector lags SPY.

CFO Taleghani put in ~$100K on Aug 11, raising his stake 27% — real C-suite money into deep weakness, RSI a washed-out 22.3 and price 30% off the 52w low after a 24% drawdown. But it's a single director-plus-CFO with no cluster, and news is negative: Q1 FY27 revenue reset, Barclays downgrade to Underweight $5, Citi Sell at $4.75, so this is a small capitulation nibble only.

CEO Cox put in ~$1.18M on Aug 10 as a brand-new open-market stake (ΔOwn 999), 2 unique insiders clustered, into a stock riding fresh momentum — Q2 beat drove a data-center-demand surge, BNP upgrade to Outperform and multiple PT hikes toward $62. RSI 57, above MA20, sector beating SPY +2.1%, clean net flow; entry only 3% above insider price. Capped at A not A+ because it's 41% off the 52w low (extended, not a bottom setup); swing target +10% to ~$28.48 within 30 days.

CEO/President Charles Fitzgerald put in $1.28M on Aug 10, raising his stake 28% — second insider buying alongside, so a real 2-person C-suite cluster. Clean net flow, buy price ($35.94) essentially at current ($36.42), profitable medical REIT with solid FFO of $1.04/share and stable 95%-leased outpatient portfolio; sits 25% off its 52w low, RSI 43, but just below MA20/50 keeps it from A+. Real estate sector is lagging SPY by ~4% and 633M debt vs 10M cash is the main watch-out.

Four-insider cluster including the CFO/GC on Aug 10, top delta 19%, buying near the $22.69 52w low (17.7% off low) with RSI 46 — insurer sits deeply off its $54.90 high. Financials sector is beating SPY by ~10%, a real tailwind, and UBS just reiterated Buy. Size is modest ($288K total across four names) and the fundamentals are shaky — Q1 net loss, negative revenue growth, and a $464.8M impairment quarter — so this is a small position only.

President/CEO Larry Wood bought ~$498K solo, delta_own 8%, single insider (no cluster) — real C-suite money into a name near its 52w low after a ~49% drawdown. Fundamentals support the thesis with 19% revenue growth and 64% gross margin, and the healthcare sector is beating SPY by ~13%. But RSI 70 is already extended into resistance at ma50, and a securities class-action lawsuit over an alleged handpiece discount program that inflated recurring revenue is a serious overhang — small position only.

CFO Lemasters bought $827K on Aug 7, raising his stake 22% — real C-suite conviction with meaningful ownership increase at exactly his purchase price. Cold-storage REIT is 32% off its 52w low, RSI 42, below both MAs but stabilizing; clean net flow. Q1 EBITDA up 3.3% with maintained guidance supports the thesis, though EPS missed and REIT sector lags SPY.

Director Cornog put in $562K on Aug 6 — a large check that raised his stake ~37% — with the stock just 5% off its 52w low and RSI at a deeply washed-out 19.8. That's a capitulation-level buy with real ΔOwn conviction and Industrials sector modestly beating SPY. Director-only (no C-suite) hard-caps this below A, and the balance sheet is ugly ($963M debt vs $14M cash, unprofitable), so it's a small swing position only.

CEO Singh put in $2.0M on Aug 6 as a brand-new open-market stake (ΔOwn 999) — a large, unambiguous conviction buy from the top operator, 6.5% below his purchase price. Stock is 48% off its 52w low but well off the bottom, sitting above ma50, RSI 44; profitable with 46% gross margin. Latest quarter showed a GAAP net loss with tariff-refund-inflated EPS and margin pressure, which caps the setup.

CEO/Director Hovde put in $1.1M with a second insider alongside, but delta_own is only 6% on an already-large stake so conviction is moderate. Deep capitulation setup: RSI 21.6, down 38% in 20 days, 33% off the 52w low but well below both MAs — a falling knife caught by real C-suite money. Recent $42M loss tied to one BaaS consumer portfolio plus a CFO departure keep this a small position, not a runner.

President/COO Abbas Mohammed bought $359K on Aug 4, raising his stake ~20% — real C-suite money after a 28% 3-month drawdown, now reclaiming both MA20 and MA50 with a positive 30-day turn. Setup weakness: RSI 69 is nearing overbought and price is 16.5% off the 52w low rather than at it, so the ideal capitulation entry has partly passed. Profitable food producer, analysts see fair value well above current, but single insider (no cluster) caps this below A.

CEO Peter Luo bought a small $85K stake (+15% ownership) with the stock above MA20/MA50 in a healthcare sector beating SPY by ~11%. But price is up 216% off its 52w low and now 12.6% above the insider's buy price, so most of the edge is gone; sub-$100K size and no cluster keep this a small watchlist-tier position.

CEO/President/Chair Newgard led a 4-unique-insider cluster (2 C-suite) buying $1.22M around $21.67, with a max ΔOwn of 161% — a genuine conviction cluster, not comp. Setup is a capitulation buy: stock is 3.9% off its 52w low after a 33% 20-day drawdown, RSI a washed-out 17.5, and current $20.39 is actually below the insiders' cost — a bank posting record Q4 net income of $7.4M with $141M cash vs $36M debt in a sector beating SPY by 7%. First target +15% to ~$23.45; if it reclaims the $28-29 MA zone there's room toward the low $30s.

CFO made a brand-new $500K stake (ΔOwn 999) at $124.52 with price now only 2.9% above his cost, RSI oversold at 29.0, and stock 13.6% off its 52w low after a 39.5% drop from highs. Real C-suite money but it's a lone buyer (cluster of 1), revenue is down 15.5% YoY, and price sits below both the 20- and 50-day MAs — a decent but imperfect falling-knife setup, so a small position only. Clean net flow and a financials sector beating SPY by 7% support the swing.

CFO Tom Timko put in ~$152K across two buys on Jul 31, raising his stake ~81% — real C-suite conviction right after the stock got cut 15% on a Q2 free-cash-flow miss (FCF flipped to -$28.9M). RSI 31.5, buying near the low end of the range, but it's a single insider well below both MAs (ma20 84, ma50 82) so this is a falling knife catch, not a clean setup. Company reaffirmed full-year outlook and p

Director Hayden bought a large $1.06M block on Jul 30, lifting his stake 34%, and current price is actually 2.2% below where he bought — decent entry with RSI ~30 after a 37% drawdown. But this is director-only with zero C-suite, and fundamentals are weak: revenue down 40.7% YoY, negative gross margin, unprofitable, debt slightly exceeds cash. Healthcare sector is beating SPY by 8.3%, but the size

CFO Tom Timko bought ~$152K on July 31, boosting his stake ~81% — meaningful conviction into a sharp selloff after Q2 met expectations but showed FCF swinging negative (-$28.9M), which knocked the stock down ~15%. Setup is a capitulation buy: RSI 31.5, ~37% off 52w low but well below both MAs, and the company reaffirmed full-year guidance with analyst targets in the $79–$100 range. Clean net flow, profitable, sector beating SPY by 4.6% — falls short of A+ only on single-insider cluster and no cluster confirmation.

CFO Taleghani put in ~$100K on Aug 11, raising his stake 27% — real C-suite money into deep weakness, RSI a washed-out 22.3 and price 30% off the 52w low after a 24% drawdown. But it's a single director-plus-CFO with no cluster, and news is negative: Q1 FY27 revenue reset, Barclays downgrade to Underweight $5, Citi Sell at $4.75, so this is a small capitulation nibble only.

CEO Cox put in ~$1.18M on Aug 10 as a brand-new open-market stake (ΔOwn 999), 2 unique insiders clustered, into a stock riding fresh momentum — Q2 beat drove a data-center-demand surge, BNP upgrade to Outperform and multiple PT hikes toward $62. RSI 57, above MA20, sector beating SPY +2.1%, clean net flow; entry only 3% above insider price. Capped at A not A+ because it's 41% off the 52w low (extended, not a bottom setup); swing target +10% to ~$28.48 within 30 days.

CEO/President Charles Fitzgerald put in $1.28M on Aug 10, raising his stake 28% — second insider buying alongside, so a real 2-person C-suite cluster. Clean net flow, buy price ($35.94) essentially at current ($36.42), profitable medical REIT with solid FFO of $1.04/share and stable 95%-leased outpatient portfolio; sits 25% off its 52w low, RSI 43, but just below MA20/50 keeps it from A+. Real estate sector is lagging SPY by ~4% and 633M debt vs 10M cash is the main watch-out.

Four-insider cluster including the CFO/GC on Aug 10, top delta 19%, buying near the $22.69 52w low (17.7% off low) with RSI 46 — insurer sits deeply off its $54.90 high. Financials sector is beating SPY by ~10%, a real tailwind, and UBS just reiterated Buy. Size is modest ($288K total across four names) and the fundamentals are shaky — Q1 net loss, negative revenue growth, and a $464.8M impairment quarter — so this is a small position only.

President/CEO Larry Wood bought ~$498K solo, delta_own 8%, single insider (no cluster) — real C-suite money into a name near its 52w low after a ~49% drawdown. Fundamentals support the thesis with 19% revenue growth and 64% gross margin, and the healthcare sector is beating SPY by ~13%. But RSI 70 is already extended into resistance at ma50, and a securities class-action lawsuit over an alleged handpiece discount program that inflated recurring revenue is a serious overhang — small position only.

CFO Lemasters bought $827K on Aug 7, raising his stake 22% — real C-suite conviction with meaningful ownership increase at exactly his purchase price. Cold-storage REIT is 32% off its 52w low, RSI 42, below both MAs but stabilizing; clean net flow. Q1 EBITDA up 3.3% with maintained guidance supports the thesis, though EPS missed and REIT sector lags SPY.

Director Cornog put in $562K on Aug 6 — a large check that raised his stake ~37% — with the stock just 5% off its 52w low and RSI at a deeply washed-out 19.8. That's a capitulation-level buy with real ΔOwn conviction and Industrials sector modestly beating SPY. Director-only (no C-suite) hard-caps this below A, and the balance sheet is ugly ($963M debt vs $14M cash, unprofitable), so it's a small swing position only.

CEO Singh put in $2.0M on Aug 6 as a brand-new open-market stake (ΔOwn 999) — a large, unambiguous conviction buy from the top operator, 6.5% below his purchase price. Stock is 48% off its 52w low but well off the bottom, sitting above ma50, RSI 44; profitable with 46% gross margin. Latest quarter showed a GAAP net loss with tariff-refund-inflated EPS and margin pressure, which caps the setup.

CEO/Director Hovde put in $1.1M with a second insider alongside, but delta_own is only 6% on an already-large stake so conviction is moderate. Deep capitulation setup: RSI 21.6, down 38% in 20 days, 33% off the 52w low but well below both MAs — a falling knife caught by real C-suite money. Recent $42M loss tied to one BaaS consumer portfolio plus a CFO departure keep this a small position, not a runner.

President/COO Abbas Mohammed bought $359K on Aug 4, raising his stake ~20% — real C-suite money after a 28% 3-month drawdown, now reclaiming both MA20 and MA50 with a positive 30-day turn. Setup weakness: RSI 69 is nearing overbought and price is 16.5% off the 52w low rather than at it, so the ideal capitulation entry has partly passed. Profitable food producer, analysts see fair value well above current, but single insider (no cluster) caps this below A.

CEO Peter Luo bought a small $85K stake (+15% ownership) with the stock above MA20/MA50 in a healthcare sector beating SPY by ~11%. But price is up 216% off its 52w low and now 12.6% above the insider's buy price, so most of the edge is gone; sub-$100K size and no cluster keep this a small watchlist-tier position.

CEO/President/Chair Newgard led a 4-unique-insider cluster (2 C-suite) buying $1.22M around $21.67, with a max ΔOwn of 161% — a genuine conviction cluster, not comp. Setup is a capitulation buy: stock is 3.9% off its 52w low after a 33% 20-day drawdown, RSI a washed-out 17.5, and current $20.39 is actually below the insiders' cost — a bank posting record Q4 net income of $7.4M with $141M cash vs $36M debt in a sector beating SPY by 7%. First target +15% to ~$23.45; if it reclaims the $28-29 MA zone there's room toward the low $30s.

CFO made a brand-new $500K stake (ΔOwn 999) at $124.52 with price now only 2.9% above his cost, RSI oversold at 29.0, and stock 13.6% off its 52w low after a 39.5% drop from highs. Real C-suite money but it's a lone buyer (cluster of 1), revenue is down 15.5% YoY, and price sits below both the 20- and 50-day MAs — a decent but imperfect falling-knife setup, so a small position only. Clean net flow and a financials sector beating SPY by 7% support the swing.

CFO Tom Timko put in ~$152K across two buys on Jul 31, raising his stake ~81% — real C-suite conviction right after the stock got cut 15% on a Q2 free-cash-flow miss (FCF flipped to -$28.9M). RSI 31.5, buying near the low end of the range, but it's a single insider well below both MAs (ma20 84, ma50 82) so this is a falling knife catch, not a clean setup. Company reaffirmed full-year outlook and p

Director Hayden bought a large $1.06M block on Jul 30, lifting his stake 34%, and current price is actually 2.2% below where he bought — decent entry with RSI ~30 after a 37% drawdown. But this is director-only with zero C-suite, and fundamentals are weak: revenue down 40.7% YoY, negative gross margin, unprofitable, debt slightly exceeds cash. Healthcare sector is beating SPY by 8.3%, but the size

CFO Tom Timko bought ~$152K on July 31, boosting his stake ~81% — meaningful conviction into a sharp selloff after Q2 met expectations but showed FCF swinging negative (-$28.9M), which knocked the stock down ~15%. Setup is a capitulation buy: RSI 31.5, ~37% off 52w low but well below both MAs, and the company reaffirmed full-year guidance with analyst targets in the $79–$100 range. Clean net flow, profitable, sector beating SPY by 4.6% — falls short of A+ only on single-insider cluster and no cluster confirmation.